Understanding how certain enzymes affect cancer treatment with cisplatin.
Novel role of APOBEC3 enzymes as key mediators of cisplatin sensitivity through aberrant processing of interstrand crosslinks
This study is looking at how certain enzymes in your body can make the chemotherapy drug cisplatin work better for treating cancers like breast cancer, especially by helping to reduce side effects and resistance to the drug, so patients can have a more effective treatment experience.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Wayne State University NIH-funded |
| Lab location | 1 site (Detroit, United States) |
| Project ID | NIH-10832515 on NIH RePORTER |
What this research studies
This research investigates the role of APOBEC3 enzymes in enhancing the effectiveness of cisplatin, a common chemotherapy drug used to treat various cancers, including breast cancer. The study focuses on how these enzymes can help overcome challenges such as drug resistance and toxicity to normal cells. By exploring the mechanisms of DNA repair pathways that interact with cisplatin, the research aims to improve patient responses to this treatment. Patients may benefit from a better understanding of how to enhance the efficacy of cisplatin therapy.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with cancers treated by cisplatin, particularly those who have experienced limited responses to current therapies.
Not a fit: Patients who are not undergoing treatment with cisplatin or who have cancers that do not respond to this drug may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment outcomes for cancer patients receiving cisplatin by reducing drug resistance and toxicity.
How similar studies have performed: Other research has shown promising results in enhancing chemotherapy efficacy through similar mechanisms, indicating that this approach has potential for success.
Where this research is happening
Detroit, United States
- Wayne State University — Detroit, United States (Active)
Researchers
- Principal investigator: Patrick, Steve M — Wayne State University
- Study coordinator: Patrick, Steve M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.